专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5948785A Heterocyclic amide compounds and pharmaceutical use of the same 失效
标题翻译：杂环酰胺化合物和药物用途相同
公开(公告)号：US5948785A
公开(公告)日：1999-09-07
申请号：US952319
申请日：1997-10-27
申请人： Fumihiko Akahoshi , Takuya Yoshimura , Masahiro Eda , Atsuyuki Ashimori , Hajime Fukuyama , Masahide Nakajima , Teruaki Imada , Hideki Okunishi , Mizuo Miyazaki
发明人： Fumihiko Akahoshi , Takuya Yoshimura , Masahiro Eda , Atsuyuki Ashimori , Hajime Fukuyama , Masahide Nakajima , Teruaki Imada , Hideki Okunishi , Mizuo Miyazaki
IPC分类号： C07D213/73 , C07D213/75 , C07D239/46 , A61K31/44 , C07D213/64
CPC分类号： C07D213/73 , C07D213/75 , C07D239/47
摘要： Heterocyclic amide compounds of the formula (I) ##STR1## wherein each symbol is as defined in the specification, pharmacologically acceptable salts thereof, pharmaceutical compositions thereof and pharmaceutical use thereof. The heterocyclic amide compounds and pharmacologically acceptable salts thereof of the present invention have superior inhibitory activity against chymase groups in mammals inclusive of human, and can be administered orally or parenterally. Therefore, they are useful as chymase inhibitors and can be effective for the prophylaxis and treatment of various diseases caused by chymase, such as those caused by angiotensin II.
摘要翻译： PCT No.PCT / JP96 / 01171 Sec。 371日期1997年10月27日第 102（e）1997年10月27日PCT PCT 1996年4月26日PCT公布。第WO96 / 33974号公报日期：1996年10月31日式（I）的杂环酰胺化合物，其中每个符号如说明书中所定义，其药理学上可接受的盐，其药物组合物和药物用途。本发明的杂环酰胺化合物及其药理学上可接受的盐对包括人在内的哺乳动物中的食糜酶基具有优异的抑制活性，可以口服或非肠道给药。因此，它们可用作胃促胰酶抑制剂，并且可用于预防和治疗由胃促胰岛素引起的各种疾病，例如由血管紧张素II引起的疾病。

2. 发明授权

US6080738A Heterocyclic amide compounds and medicinal uses thereof 失效
标题翻译：杂环酰胺化合物及其医药用途
公开(公告)号：US6080738A
公开(公告)日：2000-06-27
申请号：US284877
申请日：1999-04-22
申请人： Fumihiko Akahoshi , Atsuyuki Ashimori , Takuya Yoshimura , Masahiro Eda , Hiroshi Sakashita , Masahide Nakajima , Teruaki Imada
发明人： Fumihiko Akahoshi , Atsuyuki Ashimori , Takuya Yoshimura , Masahiro Eda , Hiroshi Sakashita , Masahide Nakajima , Teruaki Imada
IPC分类号： C07D413/12 , A61K31/435 , A61K38/00 , C07K5/078 , A61K31/505 , C07D239/47 , C07D417/12 , C07D498/04 , C07K5/04
CPC分类号： C07K5/06139 , A61K38/00
摘要： A heterocyclic amide compound of the formula (I) ##STR1## wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, a pharmaceutical composition thereof and a pharmaceutical use thereof. The heterocyclic amide compound and a pharmacologically acceptable salt thereof of the present invention have superior inhibitory action on chymase group in mammals inclusive of human, and can be administered orally or parenterally. Therefore, they are useful as chymase inhibitors and can be used for the prophylaxis and treatment of various diseases caused by chymase, such as those caused by angiotensin II.
摘要翻译： PCT No.PCT / JP97 / 03839 Sec。 371日期1999年4月22日 102（e）1999年4月22日PCT 1997年10月22日PCT公布。第WO98 / 18794号公报日期：1998年5月7日一种式（I）的杂环酰胺化合物，其中各符号如说明书中所定义，其药理学上可接受的盐，其药物组合物及其药物用途。本发明的杂环酰胺化合物及其药理学上可接受的盐对包含人的哺乳动物中的胃促胰酶组具有优异的抑制作用，可以口服或肠胃外给药。因此，它们可用作胃促胰酶抑制剂，可用于预防和治疗由胃促胰岛素引起的各种疾病，例如由血管紧张素II引起的疾病。

3. 发明授权

US5635527A Carboxylic acid compound having condensed ring, salt thereof and pharmaceutical use thereof 失效
标题翻译：具有稠环的羧酸化合物及其盐及其药物用途
公开(公告)号：US5635527A
公开(公告)日：1997-06-03
申请号：US591537
申请日：1996-02-06
申请人： Shinichiro Ono , Tomohiro Yoshida , Atsuyuki Ashimori , Keigo Kosaka , Takehiro Okada , Kazuhiro Maeda , Masahiro Eda , Fumio Mori , Yoshihisa Inoue , Hajime Ebisu , Teruaki Imada , Ruriko Ikegawa , Feng Wang , Norifumi Nakamura
发明人： Shinichiro Ono , Tomohiro Yoshida , Atsuyuki Ashimori , Keigo Kosaka , Takehiro Okada , Kazuhiro Maeda , Masahiro Eda , Fumio Mori , Yoshihisa Inoue , Hajime Ebisu , Teruaki Imada , Ruriko Ikegawa , Feng Wang , Norifumi Nakamura
IPC分类号： C07D209/42 , C07D307/84 , C07D307/85 , C07D333/62 , C07D333/68 , C07D491/04 , C07D491/048 , A61K31/715 , A61K31/34 , A61K31/38 , A61K31/40 , A61K31/405 , A61K31/44 , A61K31/445 , A61K31/55 , C07D401/12 , C07D405/12 , C07D409/12 , C08B37/16
CPC分类号： C07D491/04 , C07D209/42 , C07D307/84 , C07D307/85 , C07D333/62 , C07D333/68
摘要： A novel carboxylic acid compound having a condensed ring, which is represented by the formula (I) ##STR1## wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, a pharmaceutical composition thereof and pharmaceutical use thereof. The novel carboxylic acid compound having a condensed ring and pharmacologically acceptable salt thereof of the present invention have superior GPIIb/IIIa antagonism in mammals inclusive of human; can be administered orally; have long life in blood and low toxicity; and show less side-effects. Accordingly, they are extremely useful for the prophylaxis and treatment of thrombotic diseases and other diseases.
摘要翻译： PCT No.PCT / JP95 / 01119 Sec。 371日期1996年2月6日 102（e）日期1996年2月6日PCT归档1995年6月6日PCT公布。 WO95 / 33720 PCT公开日期1995年12月14日一种具有稠环的新型羧酸化合物，其由式（I）表示，其中每个符号如说明书中所定义，其药理学上可接受的盐，其药物组合物及其药物用途。本发明的具有稠环的新型羧酸化合物及其药理学上可接受的盐在包括人的哺乳动物中具有优异的GPIIb / IIIa拮抗作用; 可口服给药; 血液寿命长，毒性低; 并且显示较少的副作用。因此，它们对预防和治疗血栓性疾病等疾病非常有用。

4. 发明授权

US5753670A Carboxylic acid compound having condensed ring, salt thereof and pharmaceutical use thereof 失效
标题翻译：具有稠环的羧酸化合物及其盐及其药物用途
公开(公告)号：US5753670A
公开(公告)日：1998-05-19
申请号：US824541
申请日：1997-03-26
申请人： Shinichiro Ono , Tomohiro Yoshida , Atsuyuki Ashimori , Keigo Kosaka , Takehiro Okada , Kazuhiro Maeda , Masahiro Eda , Fumio Mori , Yoshihisa Inoue , Hajime Ebisu , Teruaki Imada , Ruriko Ikegawa , Feng Wang , Norifumi Nakamura
发明人： Shinichiro Ono , Tomohiro Yoshida , Atsuyuki Ashimori , Keigo Kosaka , Takehiro Okada , Kazuhiro Maeda , Masahiro Eda , Fumio Mori , Yoshihisa Inoue , Hajime Ebisu , Teruaki Imada , Ruriko Ikegawa , Feng Wang , Norifumi Nakamura
IPC分类号： C07D209/42 , C07D307/84 , C07D307/85 , C07D333/62 , C07D333/68 , C07D491/04 , C07D491/048 , A61K31/55 , A61K31/44 , C07D471/02 , C07D498/02
CPC分类号： C07D491/04 , C07D209/42 , C07D307/84 , C07D307/85 , C07D333/62 , C07D333/68
摘要： A novel carboxylic acid compound having a condensed ring; which is represented by the formula (I) ##STR1## wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, a pharmaceutical composition thereof and pharmaceutical use thereof. The novel carboxylic acid compound having a condensed ring and pharmacologically acceptable salt thereof of the present invention have superior GPIIb/IIIa antagonism in mammals inclusive of human; can be administered orally; have long life in blood and low toxicity; and show less side-effects. Accordingly, they are extremely useful for the prophylaxis and treatment of thrombotic diseases and other diseases.
摘要翻译：具有稠环的新型羧酸化合物; 其由说明书中的式（I）表示，其药理学可接受的盐，其药物组合物和药物用途。本发明的具有稠环的新型羧酸化合物及其药理学上可接受的盐在包括人的哺乳动物中具有优异的GPIIb / IIIa拮抗作用; 可口服给药; 血液寿命长，毒性低; 并且显示较少的副作用。因此，它们对预防和治疗血栓性疾病等疾病非常有用。

5. 发明授权

US5371086A Aminopyridine compounds 失效
标题翻译：氨基吡啶化合物
公开(公告)号：US5371086A
公开(公告)日：1994-12-06
申请号：US53869
申请日：1993-04-29
申请人： Tadahiro Takemoto , Masahiro Eda , Mitsuyoshi Hihara , Takehiro Okada , Hiroshi Sakashita , Miyuki Eiraku , Chikara Fukaya , Norifumi Nakamura , Masanori Sugiura , Sumio Matzno , Maki Goda , Yasumi Uchida
发明人： Tadahiro Takemoto , Masahiro Eda , Mitsuyoshi Hihara , Takehiro Okada , Hiroshi Sakashita , Miyuki Eiraku , Chikara Fukaya , Norifumi Nakamura , Masanori Sugiura , Sumio Matzno , Maki Goda , Yasumi Uchida
IPC分类号： C07D213/75 , C07D213/76 , C07D213/77 , C07D213/81 , C07D213/84 , C07D213/89 , C07D405/12 , C07D413/12 , A61K31/495 , A61K31/54 , C07D211/56 , C07D401/00
CPC分类号： C07D213/75 , C07D213/76 , C07D213/77 , C07D213/81 , C07D213/84 , C07D213/89 , C07D405/12 , C07D413/10
摘要： An aminopyridine compound represented by the formula: ##STR1## wherein n represents 0 or 1; Z represents .dbd.S, .dbd.NCN or .dbd.CHNO.sub.2 ; R.sub.1 represents --NR.sub.3 R.sub.4, --NHNR.sub.3 R.sub.4, --NHCONHR.sub.3 or --NHSO.sub.2 R.sub.3 ; R.sub.2 represents H, or substituted or unsubstituted alkyl; R.sub.3 and R.sub.4, which may be the same or different, represent H, substituted or unsubstituted alkyl, aryl, substituted or unsubstituted acyl or alkoxycarbonyl group; and R.sub.3 and R.sub.4 may form a heterocyclic ring together with a nitrogen atom to which R.sub.3 and R.sub.4 are bound, through another heteroatom or without it; an optical isomer thereof or art acid salt thereof, which is excellent in pharmacological effect and repressed in side effects as a drug for circulatory diseases.
摘要翻译：由下式表示的氨基吡啶化合物：其中n表示0或1; Z表示= S，= NCN或= CHNO2; R 1表示-NR 3 R 4，-NHNR 3 R 4，-NHCONHR 3或-NHSO 2 R 3; R 2表示H或取代或未取代的烷基; R 3和R 4可以相同或不同，表示H，取代或未取代的烷基，芳基，取代或未取代的酰基或烷氧基羰基; 并且R 3和R 4可以与R3和R4连接的氮原子一起通过另一个杂原子或不与其形成杂环; 其光学异构体或其酸性盐，其药理作用优异，作为循环系统疾病药物的副作用被抑制。

6. 发明授权

US08367695B2 Condensed tetrahydroquinoline derivative and use thereof for medical purposes 失效
标题翻译：缩合四氢喹啉衍生物及其用于医疗目的的用途
公开(公告)号：US08367695B2
公开(公告)日：2013-02-05
申请号：US12523031
申请日：2008-01-15
申请人： Masahiro Eda , Tomoko Kuroda , Keiichi Aritomo , Yoshiyuki Aoki , Satoshi Kaneko
发明人： Masahiro Eda , Tomoko Kuroda , Keiichi Aritomo , Yoshiyuki Aoki , Satoshi Kaneko
IPC分类号： A61K31/435 , A61K31/4355
CPC分类号： C07D519/00 , C07D221/16 , C07D401/04 , C07D409/04 , C07D413/04 , C07D471/04 , C07D491/04 , C07D495/04
摘要： The problem of the present invention is to provide a compound having a GR selective binding activity, which shows less action on other nuclear receptors such as progesterone receptor (PR), mineralocorticoid receptor (MR) and the like. The present invention provides a condensed tetrahydroquinoline compound represented by the following formula (I) wherein each symbol is as defined in the present specification, or a pharmaceutically acceptable salt thereof or a hydrate thereof.
摘要翻译：本发明的问题是提供具有GR选择性结合活性的化合物，其对其它核受体如孕酮受体（PR），盐皮质激素受体（MR）等显示较少的作用。本发明提供由下式（I）表示的缩合四氢喹啉化合物，其中各符号如本说明书中所定义，或其药学上可接受的盐或其水合物。

7. 发明授权

US5365344A System for transmitting data using wavelength division multiplexing 失效
标题翻译：使用波分复用传输数据的系统
公开(公告)号：US5365344A
公开(公告)日：1994-11-15
申请号：US904512
申请日：1992-06-25
申请人： Masahiro Eda , Masahiko Fujiwara
发明人： Masahiro Eda , Masahiko Fujiwara
IPC分类号： H04J14/02 , H04Q11/00
CPC分类号： H04Q11/0001 , H04J14/0227 , H04J14/0246 , H04J14/0283 , H04Q11/0066
摘要： A plurality of node apparatuses are connected by an optical transmission line. Each of the node apparatuses is assigned with a wavelength as an address different from the others. Therefore, when a first node apparatus transmits data to a second node apparatus, the data is of a wavelength corresponding to the address of the second node apparatus. The data transmission is carried out in a time slot defined by a frame pulse. The data of the corresponding wavelength is only received in the second node apparatus, and data of other wavelengths are passed through the second node apparatus. Consequently, media-access control is easily carried out independently in each node apparatus in an optical network system by using wavelength division multiplexing.
摘要翻译：多个节点装置通过光传输线路连接。每个节点设备被分配有与其他节点不同的地址的波长。因此，当第一节点装置向第二节点装置发送数据时，数据具有与第二节点装置的地址对应的波长。在由帧脉冲定义的时隙中进行数据传输。相应波长的数据仅在第二节点设备中被接收，并且其它波长的数据通过第二节点设备。因此，通过使用波分复用，能够容易地在光网络系统的各节点装置中独立进行媒体访问控制。

8. 发明申请

US20100063055A1 CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES 失效
标题翻译：浓缩四氢喹啉衍生物及其用于医疗用途
公开(公告)号：US20100063055A1
公开(公告)日：2010-03-11
申请号：US12523031
申请日：2008-01-15
申请人： Masahiro Eda , Tomoko Kuroda , Keiichi Aritomo , Yoshiyuki Aoki , Satoshi Kaneko
发明人： Masahiro Eda , Tomoko Kuroda , Keiichi Aritomo , Yoshiyuki Aoki , Satoshi Kaneko
IPC分类号： A61K31/473 , C07D221/16 , C07D413/10 , C07D401/10 , C07D471/04 , C07D487/04 , A61K31/4741 , A61K31/4985 , A61P25/00 , A61P25/22 , A61P25/24
CPC分类号： C07D519/00 , C07D221/16 , C07D401/04 , C07D409/04 , C07D413/04 , C07D471/04 , C07D491/04 , C07D495/04
摘要： The problem of the present invention is to provide a compound having a GR selective binding activity, which shows less action on other nuclear receptors such as progesterone receptor (PR), mineralocorticoid receptor (MR) and the like. The present invention provides a condensed tetrahydroquinoline compound represented by the following formula (I) wherein each symbol is as defined in the present specification, or a pharmaceutically acceptable salt thereof or a hydrate thereof.
摘要翻译：本发明的问题是提供具有GR选择性结合活性的化合物，其对其它核受体如孕酮受体（PR），盐皮质激素受体（MR）等显示较少的作用。本发明提供由下式（I）表示的缩合四氢喹啉化合物，其中各符号如本说明书中所定义，或其药学上可接受的盐或其水合物。

9. 发明授权

US5262415A Aminopyridine compounds 失效
标题翻译：氨基吡啶化合物
公开(公告)号：US5262415A
公开(公告)日：1993-11-16
申请号：US850817
申请日：1992-03-13
申请人： Tadahiro Takemoto , Masahiro Eda , Mitsuyoshi Hihara , Takehiro Okada , Hiroshi Sakashita , Miyuki Eiraku , Chikara Fukaya , Norifumi Nakamura , Masanori Sugiura , Sumio Matzno , Maki Goda , Yasumi Uchida
发明人： Tadahiro Takemoto , Masahiro Eda , Mitsuyoshi Hihara , Takehiro Okada , Hiroshi Sakashita , Miyuki Eiraku , Chikara Fukaya , Norifumi Nakamura , Masanori Sugiura , Sumio Matzno , Maki Goda , Yasumi Uchida
IPC分类号： A61K31/44 , A61K31/4406 , A61K31/4427 , A61K31/495 , A61P9/08 , A61P9/10 , A61P9/12 , C07D213/75 , C07D213/76 , C07D213/77 , C07D213/81 , C07D213/84 , C07D213/89 , C07D401/04 , C07D401/12 , C07D405/12 , C07D413/12 , A61K31/54 , C07D211/56 , C07D211/72 , C07D401/00
CPC分类号： C07D213/75 , C07D213/76 , C07D213/77 , C07D213/81 , C07D213/84 , C07D213/89 , C07D405/12 , C07D413/10
摘要： An aminopyridine compound represented by the formula: ##STR1## wherein n represents 0 or 1; Z represents .dbd.S, .dbd.O, .dbd.NCN or .dbd.CHNO.sub.2 ; R.sub.1 represents --CN, --NR.sub.3 R.sub.4, --CONR.sub.3 R.sub.4, --NHNR.sub.3 R.sub.4, --NHCONHR.sub.3, --NHSO.sub.2 R.sub.3 or --SR.sub.3 ; R.sub.2 represents H, or substituted or unsubstituted alkyl; R.sub.3 and R.sub.4, which may be the same or different, represent H, substituted or unsubstituted alkyl, aryl, substituted or unsubstituted acyl or alkoxycarbonyl group; and R.sub.3 and R.sub.4 may form a heterocyclic ring together with a nitrogen atom to which R.sub.3 and R.sub.4 are bound, through another heteroatom or without it; or an acid salt thereof, which is excellent in pharmacological effect and repressed in side effects as a drug for circulatory diseases.

10. 发明授权

US5289302A Access method for optical local area network systems 失效
标题翻译：光学局域网系统的访问方式
公开(公告)号：US5289302A
公开(公告)日：1994-02-22
申请号：US814466
申请日：1991-12-30
申请人： Masahiro Eda
发明人： Masahiro Eda
IPC分类号： H04J14/00 , H04B10/27 , H04B10/275 , H04J14/02 , H04L12/423 , H04L12/433 , H04L12/64 , H04J14/04
CPC分类号： H04J14/0227 , H04J14/0246 , H04L12/423 , H04J14/0201 , H04J14/021 , H04J14/0212 , H04J14/0283
摘要： A supervisory node (2) and non-supervisory nodes (3 through 9) are connected in a loop by an optical transmission path (1). Over the loop (1) are transferred optical signals having wavelengths of .lambda.1 through .lambda. n. An access right control packet 10 is transferred in the loop at the optical wavelength of .lambda.1. A node performing data transmission by line exchange writes its own node address (SA), the destination address (DA) and transmit reservation in the header of the access right control packet 10, and sends the packet out on the optical transmission path. The supervisory node 2 having received this access right control packet writes the wavelength to be used (.lambda.i) into the used wavelength field (UWL), and notifies the transmit and receive nodes of the choice of the wavelength. The transmit node sends data to the receive node by line exchange at the designated wavelength .lambda.i.
摘要翻译：监控节点（2）和非监督节点（3至9）通过光传输路径（1）以环路连接。在循环（1）中，传输具有（λ）1到（λ）n的波长的光信号。访问权限控制包10以（λ）1的光波长在环路中传送。通过线路交换执行数据传输的节点在访问权限控制分组10的头部中写入自己的节点地址（SA），目的地址（DA）和发送预留，并在光传输路径上发送分组。已经接收到该访问权限控制分组的监控节点2将要使用的波长（（λ）i）写入所使用的波长域（UWL）中，并且向发送和接收节点通知该波长的选择。发送节点通过在指定波长（λ）i处的线路交换来发送数据到接收节点。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式